We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CCH:LSECoca-Cola HBC AG Analysis

Data as of 2026-03-14 - not real-time

£4,548.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Coca‑Cola HBC is trading at 4,548 GBp, just below its 20‑day SMA (4,663) but comfortably above the 50‑day SMA (4,292), indicating a short‑term pull‑back within an overall bullish trend supported by increasing volume and a neutral RSI of 52. The MACD histogram is negative and the signal line is bearish, suggesting momentum may be softening near the current support around 4,398 GBp, while resistance sits near 4,890 GBp.
Fundamentally, the company delivered 7.3% revenue growth, strong gross (36.8%) and operating margins (11.7%), and a healthy ROE of 26%, underpinned by positive free cash flow and a modest payout ratio of 40%, making the 1.97% dividend appear sustainable. However, a DCF‑derived fair value of roughly 2,852 GBp implies the stock is significantly overvalued relative to its intrinsic earnings potential.
Recent material news reinforces a positive outlook: FY25 profit rose on higher volumes, the firm is boosting marketing ahead of the Winter Olympics, and a Zacks upgrade to “Buy” reflects improving earnings estimates. Moreover, the pending acquisition of Coca‑Cola Beverages Africa slated for late‑2026 could add geographic diversification and incremental growth, supporting a medium‑term upside despite current valuation concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term support with bearish MACD momentum
  • Increasing volume indicating potential breakout
  • Overvaluation relative to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and solid profitability metrics
  • Upcoming acquisition of Coca‑Cola Beverages Africa
  • Sustainable dividend and improving earnings estimates (Zacks upgrade)

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable cash‑flow generation and defensive consumer‑defensive positioning
  • Continued dividend yield with low payout ratio
  • Valuation gap that may limit upside if market re‑ratings occur

Key Metrics & Analysis

Financial Health

Revenue Growth7.30%
Profit Margin8.10%
P/E Ratio20.4
ROE25.96%
ROA7.56%
Debt/Equity99.27
P/B Ratio498.4
Op. Cash Flow£1.5B
Free Cash Flow£626.3M

Technical Analysis

TrendBullish
RSI52.4
Support£4,398.00
Resistance£4,890.00
MA 20£4,663.10
MA 50£4,291.92
MA 200£3,873.11
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value£2,852.10
Target Price£4,522.00
Upside/Downside-0.57%
GradeOvervalued
TypeBlend
Dividend Yield1.97%

Risk Assessment

Beta0.20
Volatility26.37%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.